AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
19min chapter
Psychedelic stocks: focus on their cash
Investing Experts
Navigating Psychedelic Medicine's Regulatory Landscape
This chapter examines recent challenges and developments in the psychedelic medicine sector, specifically the complex FDA approval process for MDMA therapy. It discusses the impact of an advisory panel's recommendation against Lycos's therapy on the industry's outlook and sentiment towards psychedelic stocks. Despite setbacks, the speakers remain optimistic about the long-term potential for innovative treatments, while highlighting key companies and their competitive positions in ongoing clinical trials.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode